Hépato-Gastro & Oncologie Digestive


New therapeutic options of immune-oncology and therapeutic perspectives of hepatocellular carcinoma Volume 28, supplement 1, Avril 2021


1 Hôpital de la Croix-Rousse, Service d’hépatologie et gastro-entérologie, 103 Grande rue de la Croix-Rousse, 69004 Lyon
2 INSERM U1052, Centre de Recherche sur le Cancer de Lyon, Équipe d’épigénétique et épigénomique du carcinome hépatocellulaire, Lyon
* Correspondance

Many patients with hepatocellular carcinoma will undergo systemic therapies, soon or later along the natural history of their disease. Monotherapies of tyrosine kinase inhibitors have been the only available therapies for ten years. Immuno-oncology in monotherapy has been disappointing. By contrast in therapeutic combinations, it seems very promising and the first phase-3 clinical trial showing the efficacy of the atezolizumab and bevacizumab association has become the gold-standard of systemic first line option for hepatocellular carcinoma. The phase-1/2 trials with other types of immuno-oncology-based associations (nivolumab/ipilimumab, durvalumab/trémélimumab, pembrolizumab/lenvatinib) have shown promising results, and the corresponding phase 3 trials are pending. Further, strategies of immuno-oncology-based associations are ongoing in adjuvant setting after surgery or thermo-ablations, or in addition to loco-regional approaches.